Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

Study Identifier
CANA-03-003
CT.gov Identifier
NCT00233532
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Hypertension & Blood Pressure
    • Study Drug
  • Trandolapril
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Stage 1 or 2 Hypertension
    Exclusion Criteria:
    - Uncontrolled diabetes - Subject has a hypersensitivity to ACE inhibitor

    Protocol Summary

    The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor,

    trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

    Study Locations

    No locations found.